Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GOT1 | P17174 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | VNN1 | O95497 | 1/20 | 0.33 |
| ▸ | PER2 | O15055 | 1/20 | 0.33 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.33 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LOX | P28300 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31005932 | 1.00 | GOT1 (0.35) | GOT1P2RX7VNN1PER2CRY1 | |
| SCHEMBL7345455 | 0.81 | GOT1 (0.38) | GOT1P2RX7CTDSP1CYP1A2CYP11B2 | |
| SCHEMBL329940 | 0.79 | GOT1 (0.37) | GOT1P2RX7CYP1A2CYP11B2 | |
| SCHEMBL7882127 | 0.78 | PSIP1 (0.40) | GOT1P2RX7PER2CRY1CRY2 | |
| SCHEMBL25213053 | 0.77 | ALDH1A1 (0.41) | GOT1P2RX7CYP1A2CYP11B2 | |
| SCHEMBL1076498 | 0.77 | GOT1 (0.40) | GOT1P2RX7LMNACYP1A2 | |
| SCHEMBL4460091 | 0.77 | GOT1 (0.35) | GOT1P2RX7PER2CRY1CRY2 | |
| SCHEMBL22767204 | 0.77 | GOT1 (0.35) | GOT1P2RX7PER2CRY1CRY2 | |
| SCHEMBL29892805 | 0.77 | NAPRT (0.42) | GOT1P2RX7PER2CRY1CRY2 | |
| SCHEMBL5407665 | 0.77 | NAPRT (0.42) | GOT1P2RX7PER2CRY1CRY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112367986-A | Novel lipids | 萨恩帕斯药物有限公司 | 2021-02-12 | — | — | CN | claimed |
| EP-2064204-A1 | INHIBITORS OF 5 -LIPOXYGENASE ACTIVATING PROTEIN ( FLAP) | Merck & Co., Inc. (US) | 2009-06-03 | — | — | EP | claimed |
| WO-2008030369-A1 | INHIBITORS OF 5 -LIPOXYGENASE ACTIVATING PROTEIN ( FLAP) | MERCK & CO., INC. (US) | 2008-03-13 | — | — | WO | claimed |
| CN-112367986-A | Novel lipids | 萨恩帕斯药物有限公司 | 2021-02-12 | — | — | CN | disclosed |
| CN-110869026-A | Compositions and methods for reducing cardiotoxicity | 萨恩帕斯药物有限公司 | 2020-03-06 | — | — | CN | disclosed |
| US-10308605-B2 | Proton pump inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-04 | — | — | US | disclosed |
| EP-3419971-A1 | GLYCOSIDASE INHIBITORS | Asceneuron SA (CH) | 2019-01-02 | — | — | EP | disclosed |
| EP-3419972-A1 | GLYCOSIDASE INHIBITORS | Asceneuron SA (CH) | 2019-01-02 | — | — | EP | disclosed |
| WO-2017144633-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017144639-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2017-08-31 | — | — | WO | disclosed |
| EP-2336107-B1 | Proton pump inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2015-09-23 | — | — | EP | disclosed |
| US-20080139639-A1 | 3-amino(alkyl)-substituted pyrrole compounds such as N-methyl-1-[1-(phenylsulfonyl)-5-(3-thienyl)-1H-pyrrol-3-yl]methanamine; peptic ulcer, Zollinger-Ellison syndrome, gastritis, gastroesophageal reflux disease, gastric cancer, ulcer caused by non-steroidal anti-inflammatory agent (NSAID) use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-06-12 | — | — | US | disclosed |
| US-20080139639-A1 | 3-amino(alkyl)-substituted pyrrole compounds such as N-methyl-1-[1-(phenylsulfonyl)-5-(3-thienyl)-1H-pyrrol-3-yl]methanamine; peptic ulcer, Zollinger-Ellison syndrome, gastritis, gastroesophageal reflux disease, gastric cancer, ulcer caused by non-steroidal anti-inflammatory agent (NSAID) use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-06-12 | — | — | US | disclosed |
| EP-1803709-A1 | PROTON PUMP INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2007-07-04 | — | — | EP | disclosed |
| US-20070060623-A1 | antiulcer agents; proton pump inhibitors; side effect reduction; 1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine; superior acid secretion inhibitory effect; peptic ulcer, Zollinger-Ellison syndrome, reflux esophagitis, or symptomatic gastroesophageal reflux disease | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | disclosed |
| US-20070060623-A1 | antiulcer agents; proton pump inhibitors; side effect reduction; 1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine; superior acid secretion inhibitory effect; peptic ulcer, Zollinger-Ellison syndrome, reflux esophagitis, or symptomatic gastroesophageal reflux disease | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | disclosed |
| WO-2007026916-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-08 | — | — | WO | disclosed |
| US-5776858-A | HERBICIDES | NIHON BAYER AGROCHEM K.K. (JP) | 1998-07-07 | — | — | US | disclosed |
| EP-0771797-A1 | 1-Azinyl-tetrazolinone herbicides | NIHON BAYER AGROCHEM K.K. (JP) | 1997-05-07 | — | — | EP | disclosed |
| US-4267174-A | AND PROCESS FOR ADMINISTERING | BOEHRINGER MANNHEIM, GMBH (DE) | 1981-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308605-B2 | Proton pump inhibitors | HRH2, HRH4, HRH1 | GOT1 2045/4885P2RX7 668/4885VNN1 987/4885 |
| US-20080139639-A1 | 3-amino(alkyl)-substituted pyrrole compounds such as N-methyl-1-[1-(phenylsulfonyl)-5-(3-thienyl)-1H-pyrrol-3-yl]methanamine; peptic ulcer, Zollinger-Ellison syndrome, gastritis, gastroesophageal reflux disease, gastric cancer, ulcer caused by non-steroidal anti-inflammatory agent (NSAID) use | PTGER1, PTGER3, NR3C1 | GOT1 1238/4885P2RX7 734/4885VNN1 2035/4885 |
| US-20070060623-A1 | antiulcer agents; proton pump inhibitors; side effect reduction; 1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine; superior acid secretion inhibitory effect; peptic ulcer, Zollinger-Ellison syndrome, reflux esophagitis, or symptomatic gastroesophageal reflux disease | HRH2, GIPR, HRH4 | GOT1 2371/4885P2RX7 1501/4885VNN1 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.